Physician profile
Herbert Patrick
NPI 1811938558
$47,504.08
in general payments reported to CMS, 2019-2025
16 companies · $13.77 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $14K · 2021: $5,480 · 2022: $1,142 · 2023: $6,890 · 2024: $38.96 · 2025: $13.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,508 · Food and Beverage: $291 · Travel and Lodging: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,508.33 |
| Food and Beverage | $291.20 |
| Travel and Lodging | $143.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $43,135.56 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $1,875.00 | 2021 | |
| Medtronic, INC. | $516.67 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $508.33 | 2023 | |
| Bard Peripheral Vascular, INC. | $300.00 | 2019 | |
| Bard Access Systems, INC. | $300.00 | 2020 | |
| Resmed Corp | $250.00 | 2022 | |
| Covidien Lp | $201.55 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $121.22 | 2022 | |
| Fisher & Paykel Healthcare INC | $78.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $72.55 | 2020-2022 | |
| Allergan, INC. | $53.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.61 | 2024-2025 | Jardiance |
| Abbvie INC. | $21.82 | 2023 | |
| Csl Behring | $16.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.